Amyris, Inc. AMRS
We take great care to ensure that the data presented and summarized in this overview for AMYRIS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMRS
View all-
Strategic Wealth Advisors Group, LLC Sacramento, CA104KShares$1,0400.01% of portfolio
-
Kore Private Wealth LLC New York, NY51KShares$5100.03% of portfolio
-
Endurance Wealth Management, Inc.37.5KShares$3740.0% of portfolio
-
Balasa Dinverno & Foltz LLC Itasca, IL23.7KShares$2370.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V813.3KShares$1320.0% of portfolio
-
Wipfli Financial Advisors Llc,547Shares$50.0% of portfolio
-
Sargent Bickham Lagudis LLC23Shares$00.0% of portfolio
Latest Institutional Activity in AMRS
Top Purchases
Top Sells
About AMRS
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Insider Transactions at AMRS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
May 07
2024
|
Steven Richard Mills |
SELL
Other acquisition or disposition
|
Indirect |
10,316
-100.0%
|
-
|
|
May 07
2024
|
Steven Richard Mills |
SELL
Other acquisition or disposition
|
Direct |
27,088
-100.0%
|
-
|
|
May 07
2024
|
Geoffrey M Duyk |
SELL
Other acquisition or disposition
|
Direct |
40,552
-100.0%
|
-
|
|
May 07
2024
|
Frank Kung |
SELL
Other acquisition or disposition
|
Indirect |
7,750,828
-100.0%
|
-
|
|
May 07
2024
|
Julie Washington |
SELL
Other acquisition or disposition
|
Direct |
19,166
-100.0%
|
-
|
|
May 07
2024
|
Lisa Qi |
SELL
Other acquisition or disposition
|
Direct |
37,471
-100.0%
|
-
|
|
May 07
2024
|
Ana Dutra |
SELL
Other acquisition or disposition
|
Direct |
10,950
-100.0%
|
-
|
|
May 07
2024
|
James F Mccann |
SELL
Other acquisition or disposition
|
Direct |
46,913
-100.0%
|
-
|
|
May 07
2024
|
Hermanus Kieftenbeld CFO AND INTERIM CEO |
SELL
Other acquisition or disposition
|
Direct |
123,102
-100.0%
|
-
|
|
May 07
2024
|
Ryan Panchadsaram |
SELL
Other acquisition or disposition
|
Direct |
35,785
-100.0%
|
-
|
|
May 07
2024
|
L John Doerr |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
90,864,741
-100.0%
|
-
|
|
May 07
2024
|
L John Doerr |
SELL
Sale (or disposition) back to the issuer
|
Direct |
46,047
-100.0%
|
-
|
|
Jun 02
2023
|
Hermanus Kieftenbeld CFO AND INTERIM CEO |
SELL
Open market or private sale
|
Direct |
20,999
-4.42%
|
$0
$0.95 P/Share
|
|
Apr 19
2023
|
James F Mccann |
BUY
Grant, award, or other acquisition
|
Direct |
13,437
+8.52%
|
-
|
|
Apr 19
2023
|
L John Doerr |
BUY
Grant, award, or other acquisition
|
Direct |
11,600
+8.43%
|
-
|
|
Apr 19
2023
|
Lisa Qi |
BUY
Grant, award, or other acquisition
|
Direct |
10,537
+8.23%
|
-
|
|
Apr 19
2023
|
Ryan Panchadsaram |
BUY
Grant, award, or other acquisition
|
Direct |
9,667
+7.71%
|
-
|
|
Apr 05
2023
|
Eduardo Alvarez CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
231,368
-27.42%
|
$231,368
$1.23 P/Share
|
|
Apr 04
2023
|
Eduardo Alvarez CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
492,000
+36.83%
|
-
|
|
Jan 20
2023
|
Lisa Qi |
BUY
Grant, award, or other acquisition
|
Direct |
7,532
+6.58%
|
-
|
Last 12 Months Summary
| Sale (or disposition) back to the issuer | 90.9M shares |
|---|---|
| Other acquisition or disposition | 8.1M shares |